新辅助化疗在晚期卵巢癌患者管理中的作用：妇科肿瘤学家协会成员的调查结果，一项5年随访研究
The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up.
作者信息
Huelsmann Erica, Zighelboim Israel, Ahmed Amina, Dewdney Summer
机构信息
Department of Obstetrics and Gynecology, MedStar Washington Hospital Center/MedStar Georgetown University Hospital, United States.
Department of Gynecologic Oncology, St. Luke's Cancer Care Associates, Temple University School of Medicine, United States.
出版信息
Gynecol Oncol Rep. 2017 Feb 16;20:47-50. doi: 10.1016/j.gore.2017.02.005. eCollection 2017 May.
Abstract
•NACT use among SGO members for ovarian cancer is explored given recent trials.•Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.•Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.•Very high optimal cytoreduction rates are reported from SGO members.•Despite recent studies, SGO members don't regularly treat patients with NACT/ID.
摘要
•鉴于近期的试验，探讨了妇科肿瘤学家协会（SGO）成员对卵巢癌使用新辅助化疗（NACT）的情况。
•更少的SGO成员认为他们无法在术前预测最佳细胞减灭术。
•腹腔镜检查在卵巢癌诊断和治疗中的使用有所增加。
•SGO成员报告的最佳细胞减灭率非常高。
•尽管有近期的研究，但SGO成员并不经常对患者进行新辅助化疗/间隔期肿瘤细胞减灭术（NACT/ID）治疗。
相似文献
1
The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up.新辅助化疗在晚期卵巢癌患者管理中的作用：妇科肿瘤学家协会成员的调查结果，一项5年随访研究
Gynecol Oncol Rep. 2017 Feb 16;20:47-50. doi: 10.1016/j.gore.2017.02.005. eCollection 2017 May.
2
The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.新辅助化疗在晚期卵巢癌患者管理中的作用：妇科肿瘤学家学会成员的调查结果。
Gynecol Oncol. 2010 Oct;119(1):18-21. doi: 10.1016/j.ygyno.2010.06.021. Epub 2010 Jul 31.
3
What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?治疗晚期上皮性卵巢癌的妇科肿瘤学家目前的手术目标、策略和技术能力是什么？
Gynecol Oncol. 2001 Sep;82(3):489-97. doi: 10.1006/gyno.2001.6312.
4
Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training.妇科肿瘤学家协会成员及培训学员在妇科肿瘤领域的腹腔镜培训与实践。
Gynecol Oncol. 2004 Sep;94(3):746-53. doi: 10.1016/j.ygyno.2004.06.011.
5
Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.FIGO IIIC期和IV期患者的新辅助化疗或初次肿瘤减灭术；荷兰一项调查研究的结果
Eur J Obstet Gynecol Reprod Biol. 2018 Apr;223:98-102. doi: 10.1016/j.ejogrb.2018.02.029. Epub 2018 Mar 6.
6
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.高级别晚期卵巢癌的初次肿瘤细胞减灭术与初次新辅助化疗：生存比较。
Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.
7
Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer.晚期上皮性卵巢癌先行新辅助化疗，随后进行肿瘤细胞减灭术。
Indian J Cancer. 2006 Jul-Sep;43(3):117-21. doi: 10.4103/0019-509x.27933.
8
Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology.新辅助化疗在 IIIC-IV 期卵巢癌治疗中的作用：欧洲妇科肿瘤学会成员的调查结果。
Int J Gynecol Cancer. 2012 Mar;22(3):407-16. doi: 10.1097/IGC.0b013e31823ea1d8.
9
Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.新辅助化疗使晚期卵巢癌的最佳减瘤率与直接手术相当，但不能提高生存率。
Arch Gynecol Obstet. 2013 Dec;288(6):1399-403. doi: 10.1007/s00404-013-2924-7. Epub 2013 Jun 18.
10
Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.将机器人手术纳入新辅助化疗后卵巢癌的治疗管理中。
Int J Gynecol Cancer. 2019 Nov;29(9):1341-1347. doi: 10.1136/ijgc-2019-000413. Epub 2019 Oct 9.
引用本文的文献
1
Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.晚期卵巢癌手术：初次减瘤术与间隔期减瘤术
Diagnostics (Basel). 2022 Apr 14;12(4):988. doi: 10.3390/diagnostics12040988.
2
The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery.新辅助化疗或初次肿瘤细胞减灭术治疗晚期上皮性卵巢癌的残余肿瘤的预后影响。
Cancer Med. 2022 Jul;11(14):2836-2845. doi: 10.1002/cam4.4642. Epub 2022 Mar 10.
3
Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016.2004 年至 2016 年美国晚期上皮性卵巢癌女性患者的一线治疗趋势和中位生存情况。
JAMA Netw Open. 2020 Sep 1;3(9):e2017517. doi: 10.1001/jamanetworkopen.2020.17517.
4
detection of potential prognostic circRNAs through a re-annotation strategy in ovarian cancer.通过重新注释策略检测卵巢癌中潜在的预后环状RNA
Oncol Lett. 2019 Apr;17(4):3677-3686. doi: 10.3892/ol.2019.10021. Epub 2019 Feb 6.
本文引用的文献
1
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.OV21/PETROC：一项新辅助化疗和最佳肿瘤细胞减灭术后腹腔内与静脉化疗在卵巢上皮癌中的随机妇科癌症协作组 II 期研究。
Ann Oncol. 2018 Feb 1;29(2):431-438. doi: 10.1093/annonc/mdx754.
2
What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?在晚期卵巢癌的间隔期或初次肿瘤细胞减灭术中进行完全肿瘤细胞减灭术后，我们应期待什么？
Ann Surg Oncol. 2016 May;23(5):1666-73. doi: 10.1245/s10434-015-5051-9. Epub 2015 Dec 29.
3
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.新诊断的晚期卵巢癌的初次化疗与初次手术（CHORUS）：一项开放标签、随机、对照、非劣效性试验。
Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19.
4
Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.新诊断晚期上皮性卵巢癌患者最佳肿瘤细胞减灭术的预测因素：是时候将腹腔镜评估纳入护理标准了。
Gynecol Oncol. 2015 Jun;137(3):553-8. doi: 10.1016/j.ygyno.2015.03.049. Epub 2015 Mar 28.
5
Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.新辅助化疗在晚期卵巢癌中的应用：最新结果和治疗地位。
Ther Adv Med Oncol. 2014 Nov;6(6):293-304. doi: 10.1177/1758834014544891.
6
Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?晚期上皮性卵巢癌的初次手术或间隔减瘤术：有关系吗？
Int J Gynecol Cancer. 2014 Oct;24(8):1420-8. doi: 10.1097/IGC.0000000000000241.
7
Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.对于晚期卵巢癌患者，行初次肿瘤细胞减灭术或新辅助化疗后行间隔性肿瘤细胞减灭术。
Chin J Cancer Res. 2012 Dec;24(4):304-9. doi: 10.3978/j.issn.1000-9604.2012.09.02.
8
Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.在 IV 期卵巢癌中，初次肿瘤细胞减灭术与新辅助化疗的比较。
Ann Surg Oncol. 2012 Mar;19(3):959-65. doi: 10.1245/s10434-011-2100-x. Epub 2011 Oct 13.
9
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).分析同期接受根治性手术（PDS）与新辅助化疗（NACT）随机 EORTC-NCIC 试验的大块晚期卵巢、输卵管和腹膜癌患者。
Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.
10
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?新辅助化疗后行满意肿瘤细胞减灭术的上皮性卵巢癌患者行腹腔化疗是否获益？
Gynecol Oncol. 2011 Jun 1;121(3):451-4. doi: 10.1016/j.ygyno.2011.02.016. Epub 2011 Mar 12.
Zotero 插件